mansakhalifa:


I will address your concerns one after the other:

1. Antartica. Forget the humans living three temporarily. There are still other creatures over there that the gospel can still be preached to. The penguins for instance. At the end of the day, you would have gone into the record books as the first person to preach the gospel in Antarctica one way or another.

2. Yes. People still live deep in the Amazon- thousands of them- and they are largely uncontacted by anyone from the outside world. Many of them don't even know we exist. Let alone what the gospel is. Not even the early Portuguese colonists- zealous as they were to spread the gospel- of the 16th/17th/18th century could reach them.
So, what better way to look for new grounds to spread the gospel?

3. India. Well, there are Christians in mainland India, so you don't need to go there. That was why I specifically advised the OP to try the preaching to the inhabitants of the North Sentinel Island. Very friendly guys, those people. Just go with enough coconuts and learn how to dodge flying arrows properly.
That's all.

And dodge the bullets of Indian military and police .

There are only 50 sentinelese left , they will die of diseases if they come in contact with modern humans .

So leave them alone evangelist barbarians and murderers .

emotionada:


They are talking of the earth.

What makes you thing I am not talking about earth



Hell and heaven are both what we make of our and others lives right here on earth


If you want to see hell I will point you to the nearest church and mosque where human misery is taken advantage of in the name of so called god and religion.

You all be the judge


When our ancestors were killed by the millions in the name of the very same god's to who we bow to now , it was hell for them , but now it is heaven for us . See the irony .

buzorcharles:
Yes. At the NORTH SENTINEL ISLAND. An island very close to india that kills any visitor that comes close enough. Many evangelists has been killed by those barberians

You mean barbarian evangelists got killed by humans since not long ago same barbarian evangelists were killing and converting our ancestors. Now we are nothing but slaves to their gods and their preachers .
How far have we fallen ! Rejoicing at our mental slavery


Serves them right , good riddance to bad rubbish

davit:
I'm interested in this island.

Under protection by Indian military and police. Illegal to to come within 100 km radius of the prohibited zone.

Shoot to kill any foreigners trying to enter prohibited zone.

Plus10:
Jesus said in Matthew 24:14 that the end will come when the gospel has been preached to all nations of the Earth.

My question is "are there nations or places where the gospel has not been preached?

HELL............

YOU ARE MOST WELCOMED TO TRY THERE

Mumus don rule our naija

gretblue:

I don't watch zee world and Africa magic at home.
The WHO Representative was clear yesterday on Channels PTF Covid 19 briefing.
Nigeria has joined the other nations to develop Covid 19 vaccines. That means Prof IWu and other scientists in Nigeria can develop vaccines for Covid 19.
Don't die of your ignorance especially news that you don't follow or listen to it

What will naija contribute to WHO when WHO is not developing any vaccines for COVID 19 biko ?

WHO is coordinating worldwide for human trials for extensive testing due to geo specific mutations of COVID 19 and pooling of resultant clinical data.

COVID 19 vaccines are being developed for trials by MNC companies and state funded R & D institutions in USA , CHINA , INDIA , SOUTH KOREA , EU , UK only .

Name one Nigerian pharma company doing research on COVID 19 ?

Audiooo research smh

Where is the advanced R & D bio facilities in Nigeria ?

COVID 19 research requires bio safety level BSL - 4 facilities .

Nigeria has none !!!!!!

In Africa only south africa have one BSL-4 lab .

abeg what more to expect when corruption rules the roost in naija and mediocrity is rewarded , now reduced to providing guinea pigs for clinical trials only and false chest beating .

Smh

Getoverit1:




Fake news and naija be like 5&6

Remdesivir was created and developed by Gilead Sciences, under the direction of scientist Tomáš Cihlář who is an Czech American .

Google it if you don't believe it .

i tire too oo

Press release from Gilead Sciences Inc

Gilead Announces Results From Phase 3 Trial of Investigational Antiviral Remdesivir in Patients With Severe COVID-19

-- Study Demonstrates Similar Efficacy with 5- and 10-Day Dosing Durations of Remdesivir --

Merdad Parsey, MD, PhD, Chief Medical Officer, Gilead Sciences

Aruna Subramanian, MD, Clinical Professor of Medicine, Chief, Immunocompromised Host Infectious Diseases, Stanford University School of Medicine, and lead investigators of the study.



FOSTER CITY, Calif.--(BUSINESS WIRE)--Apr. 29, 2020-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced topline results from the open-label, Phase 3 SIMPLE trial evaluating 5-day and 10-day dosing durations of the investigational antiviral remdesivir in hospitalized patients with severe manifestations of COVID-19 disease. The study demonstrated that patients receiving a 10-day treatment course of remdesivir achieved similar improvement in clinical status compared with those taking a 5-day treatment course (Odds Ratio: 0.75 [95% CI 0.51 – 1.12] on Day 14). No new safety signals were identified with remdesivir across either treatment group. Gilead plans to submit the full data for publication in a peer-reviewed journal in the coming weeks.

“Unlike traditional drug development, we are attempting to evaluate an investigational agent alongside an evolving global pandemic. Multiple concurrent studies are helping inform whether remdesivir is a safe and effective treatment for COVID-19 and how to best utilize the drug,” said Merdad Parsey, MD, PhD, Chief Medical Officer, Gilead Sciences.

“These study results complement data from the placebo-controlled study of remdesivir conducted by the National Institute for Allergy and Infectious Diseases and help to determine the optimal duration of treatment with remdesivir. The study demonstrates the potential for some patients to be treated with a 5-day regimen, which could significantly expand the number of patients who could be treated with our current supply of remdesivir. This is particularly important in the setting of a pandemic, to help hospitals and healthcare workers treat more patients in urgent need of care.”

Remdesivir is not yet licensed or approved anywhere globally and has not yet been demonstrated to be safe or effective for the treatment of COVID-19. This study sought to determine whether a shorter, 5-day course of remdesivir would achieve similar efficacy results as the 10-day treatment regimen used in multiple ongoing studies of remdesivir. Secondary objectives included rates of adverse events and additional measures of clinical response in both treatment groups. Patients were required to have evidence of pneumonia and reduced oxygen levels that did not require mechanical ventilation at the time of study entry. Clinical improvement was defined as an improvement of two or more points from baseline on a predefined seven-point scale, ranging from hospital discharge to increasing levels of oxygen support to death. Patients achieved clinical recovery if they no longer required oxygen support and medical care or were discharged from the hospital.

In this study, the time to clinical improvement for 50 percent of patients was 10 days in the 5-day treatment group and 11 days in the 10-day treatment group. More than half of patients in both treatment groups were discharged from the hospital by Day 14 (5-day: 60.0%, n=120/200 vs.10-day: 52.3% n=103/197; p=0.14). At Day 14, 64.5 percent (n=129/200) of patients in the 5-day treatment group and 53.8 percent (n=106/197) of patients in the 10-day treatment group achieved clinical recovery.

Clinical outcomes varied by geography. Outside of Italy, the overall mortality rate at Day 14 was 7 percent (n=23/320) across both treatment groups, with 64 percent (n=205/320) of patients experiencing clinical improvement at Day 14 and 61 percent (n=196/320) of patients discharged from the hospital.

In an exploratory analysis, patients in the study who received remdesivir within 10 days of symptom onset had improved outcomes compared with those treated after more than 10 days of symptoms. Pooling data across treatment arms, by Day 14, 62 percent of patients treated early were able to be discharged from the hospital, compared with 49 percent of patients who were treated late.

“These data are encouraging as they indicate that patients who received a shorter, 5-day course of remdesivir experienced similar clinical improvement as patients who received a 10-day treatment course,” said Aruna Subramanian, MD, Clinical Professor of Medicine, Chief, Immunocompromised Host Infectious Diseases, Stanford University School of Medicine, and one of the lead investigators of the study.


“While additional data are still needed, these results help to bring a clearer understanding of how treatment with remdesivir may be optimized, if proven safe and effective.”

Remdesivir was generally well-tolerated in both the 5-day and 10-day treatment groups. The most common adverse events occurring in more than 10 percent of patients in either group were nausea (5-day: 10.0%, n=20/200 vs. 10-day: 8.6%, n=17/197) and acute respiratory failure (5-day: 6.0%, n=12/200 vs. 10-day: 10.7%, n= 21/197). Grade 3 or higher liver enzyme (ALT) elevations occurred in 7.3 percent (n=28/385) of patients, with 3.0 percent (n=12/397) of patients discontinuing remdesivir treatment due to elevated liver tests.